MedTrace Logo

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551

NCT00860353 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of this study is to determine how well tolerated and safe AZD2551 is at different dose levels in healthy, non-smoking males. It will also investigate how quickly AZD2551 is absorbed into and cleared by the body

Conditions

  • Healthy

Interventions

DRUG

AZD2551

Single dose of oral solution.

DRUG

Placebo

Single dose of oral solution

Sponsors & Collaborators

Principal Investigators

  • William Fahy, MA, MBBS (Hons) · AstraZeneca Clinical Pharmacology Unit, E Floor, Queens Medical Centre, Nottingham NG7 2UH

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Completion
2009-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860353 on ClinicalTrials.gov